Downstream Processing Featured Articles

31. Crucell And Scripps Research Discover And Describe Broad-Spectrum Antibodies Against Influenza B, A Crucial Link In Development Of Universal Flu Therapies And Vaccine 8/9/2012

    In a landmark discovery, researchers from Crucell Holland B.V. and The Scripps Research Institute, recently announced the identification of the first human monoclonal antibodies that appear capable of disabling all influenza B viruses. 

32. Aeras Signs Agreement With GSK To Jointly Advance TB Vaccine 10/10/2012

    Aeras announces that it has signed an agreement with GlaxoSmithKline Vaccines, S.A. (GSK) to jointly advance the clinical development of an investigational tuberculosis (TB) vaccine containing GSK’s proprietary M72 antigen and AS01E adjuvant.

33. Rare Cancers Yield Potential Source Of Tumor Growth 9/17/2012

    Researchers at the National Institutes of Health have discovered a genetic mutation that appears to increase production of red blood cells in tumors.

34. Seminars, Technology Highlight CYTO 2013 Offerings From Beckman Coulter Life Sciences 5/16/2013

    Presenting two seminars and seven poster sessions, Beckman Coulter Life Sciences will have a prominent role when CYTO 2013 convenes at the San Diego Convention Center May 18-22, 2013.

35. Advanced BioScience Laboratories Awards Avid Bioservices HIV Vaccine Development And Manufacturing Contract 9/27/2012

    Avid Bioservices, a subsidiary of Peregrine Pharmaceuticals, Inc., today announced that it has been chosen by Advanced BioScience Laboratories, Inc. (ABL) to provide development and large-scale manufacturing services to support cGMP production of an HIV envelope protein, as a component of a preventive vaccine against HIV infection.

36. Millipore's Montage DNA Gel Extraction Kit Maximizes DNA Recovery from Agarose Gel Slices 7/26/2002
    10-minute spin yields fully functional DNA50 x modified TAE buffer available with the kit...
37. Phenex Enters Into A Research Collaboration And License Agreement With Janssen For Autoimmune And Chronic Inflammatory Disorders 12/17/2012

    Phenex Pharmaceuticals AG (Phenex) today announced it has entered into an agreement with Janssen Biotech, Inc. and its affiliates (Janssen) to jointly discover compounds that target the nuclear hormone receptor RORγT and may have utility in the treatment of chronic autoimmune and inflammatory disorders including rheumatoid arthritis, psoriasis, and inflammatory bowel disease.

38. Biosensors & Big Data: Implications For Biologics Developers 10/13/2020

    Dr. Caroline Loew’s company, Glympse Bio, develops injectable, tunable biosensors that she says will help biologics developers test and measure disease progression in vivo, enabling valuable, early visibility into therapeutic efficacy. 

39. Launch Of A New Protein A Chromatography Resin For Purification Of Antibody Drugs 10/2/2012

    Kaneka Corporation (Osaka, Japan; President: Kimikazu Sugawara ) announces the launch of KANEKA KanCapA, a new Protein A Chromatography Resin for the purification of therapeutic antibodies. 'KANEKA KanCapA' exhibits high antibody adsorbing capacity and alkaline resistance.

40. Frost & Sullivan Lauds Pfenex Inc. For Developing A Protein Expression Platform That Delivers Unparalleled Success And Speed 6/5/2012

    Based on its comprehensive  TEAM Research rigorous 10 step evaluation methodology, Frost & Sullivan has awarded Pfenex Inc. with the 2012 North American Enabling Technology Award in Microbial Expression Technology.